• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Essential Evidence-Based Psychopharmacology

Essential Evidence-Based Psychopharmacology

9781107400108
396.84 zł
357.15 zł Save 39.69 zł Tax included
Lowest price within 30 days before promotion: 357.15 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimers disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
Product Details
66696
9781107400108
9781107400108

Data sheet

Publication date
2012
Issue number
2
Cover
paperback
Pages count
334
Dimensions (mm)
155.00 x 231.00
Weight (g)
500
  • Preface; Foreword; 1. Evidence-based pharmacotherapy of attention deficit hyperactivity disorder Brigitte S. Vaughan, John S. March and Christopher J. Kratochvil; 2. Evidence-based pharmacotherapy of schizophrenia Stefan Leucht, Stephan Heres, Werner Kissling and John M. Davis; 3. Evidence-based pharmacotherapy of bipolar disorder Matthew J. Taylor and John R. Geddes; 4. Evidence-based pharmacotherapy of major depressive disorder Jamie M. Dupuy, Michael J. Ostacher, Jeffrey Huffman, Roy H. Perlis and Andrew A. Nierenberg; 5. Evidence-based pharmacotherapy of panic disorder Neeltje M. Batelaan, Anton J. L. M. Van Balkom and Dan J. Stein; 6. Evidence-based pharmacotherapy of social anxiety disorder Carlos Blanco, Laura B. Bragdon, Franklin R. Schneier and Michael R. Liebowitz; 7. Evidence-based pharmacotherapy of generalised anxiety disorder David S. Baldwin, Sarah Waldman and Christer Allgulander; 8. Evidence-based pharmacotherapy of obsessive-compulsive disorder Naomi A. Fineberg, Angus Brown and Ilenia Pampaloni; 9. Evidence-based pharmacotherapy of posttraumatic stress disorder Jonathan C. Ipser and Dan J. Stein; 10. Evidence-based pharmacotherapy of eating disorders Martine F. Flament, Hany Bissada and Wendy Spettigue; 11. Evidence-based pharmacotherapy of nicotine and alcohol dependence Wim van den Brink; 12. Evidence-based pharmacotherapy of illicit substance use disorders Wim van den Brink; 13. Evidence-based pharmacotherapy of Alzheimers disease Darren Cotterell and Martin Brown; 14. Evidence-based pharmacotherapy of personality disorders Luis H. Ripoll, Joseph Triebwasser and Larry J. Siever; Index.
Comments (0)